MedPath

Ofloxacin

Generic Name
Ofloxacin
Brand Names
Ocuflox
Drug Type
Small Molecule
Chemical Formula
C18H20FN3O4
CAS Number
82419-36-1
Unique Ingredient Identifier
A4P49JAZ9H

Overview

A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.

Background

A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.

Indication

For the treatment of infections (respiratory tract, kidney, skin, soft tissue, UTI), urethral and cervical gonorrhoea.

Associated Conditions

  • Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB)
  • Acute Otitis Media (AOM)
  • Bacterial Infections
  • Cervicitis
  • Community Acquired Pneumonia (CAP)
  • Complicated Urinary Tract Infection
  • Conjunctivitis
  • Epididymitis
  • Hansen's Disease
  • Nongonococcal urethritis
  • Otitis Externa
  • Prostatitis
  • Skin and Subcutaneous Tissue Bacterial Infections
  • Spontaneous Bacterial Peritonitis (SBP)
  • Traveler's Diarrhea
  • Ulcerative keratitis
  • Acute Pelvic inflammatory disease
  • Acute, uncomplicated Gonorrhea
  • Chronic suppurative Otitis media
  • Uncomplicated Cystitis

FDA Approved Products

Ofloxacin Otic
Manufacturer:Apotex Corp.
Route:AURICULAR (OTIC)
Strength:3 mg in 1 mL
Approved: 2023/12/04
NDC:60505-0363
Ofloxacin
Manufacturer:ARMAS PHARMACEUTICALS INC.
Route:OPHTHALMIC
Strength:3 mg in 1 mL
Approved: 2023/10/23
NDC:72485-613
Ofloxacin Otic
Manufacturer:NuCare Pharmaceuticals,Inc.
Route:AURICULAR (OTIC)
Strength:3 mg in 1 mL
Approved: 2021/02/11
NDC:68071-1630
Ofloxacin ophthalmic
Manufacturer:Altaire Pharmaceuticals Inc.
Route:OPHTHALMIC
Strength:3 mg in 1 mL
Approved: 2022/10/31
NDC:59390-140
OFLOXACIN
Manufacturer:DIRECT RX
Route:OPHTHALMIC
Strength:3 mg in 1 mL
Approved: 2015/11/05
NDC:61919-175

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath